114 results on '"SINGH, N."'
Search Results
2. Post-Kidney Transplant Neutropenia After Alemtuzumab Induction: Risk Factors and Graft Outcomes.
3. PREDICTORS OF NEW ONSET DIABETES AFTER PANCREAS TRANSPLANT
4. Role of Thrombocytopenia as a Contributor to Early Infectious Morbidity in Liver Transplant Recipients.
5. Predicting Bacteremia and Mortality in Bacteremic Liver Transplant Recipients.
6. Post-transplant Alcohol Use is an Independent Risk-Factor for Late-onset Renal Failure in Liver Transplant Recipients with Hepatitis C Virus Infection.
7. Changes in the Level of CMV Antigenemia (pp65) in Liver Transplant Recipients Receiving Oral Ganciclovir as CMV Prophylaxis
8. Pneumonia in Liver Transplant Recipients in the Intensive Care Unit (ICU): Etiology, Predictors and Outcome.
9. Thrombocytopenia in Liver Transplant Recipients: Role of Endogenous Thrombopoietin.
10. Immunosuppressive Associated Leukoencephalopathy in Organ Transplant Recipients.
11. INFLUENCE OF HEPATITIS C VIRUS (HCV) RECURRENCE ON QUALITY OF LIFE (QOL) OF LONG-TERM LIVER TRANSPLANT SURVIVORS.
12. Brain Abscesses in Liver Transplant Recipients: Prospective, Multicenter Study with Implications for Management
13. CMV Antigenemia Directed Preemptive Prophylaxis with Oral Ganciclovir for the Prevention of CMV Disease in Liver Transplant Recipients: A Prospective, Randomized, Controlled Trial
14. Quality of Life and Functional Status of Liver Transplant Recipients with Recurrent Hepatitis C Virus (HCV) Hepatitis
15. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management
16. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil.
17. T Cells Engineered to Display on their Surface a Novel Form of Fasl Fail to Induce GVHD Following Transplantation Into Irradiated Allogeneic Hosts.
18. PROSPECTIVE ASSESSMENT OF PLATELIA™ ASPERGILLUS EIA IN THE BRONCHOALVEOLAR LAVAGE FLUID FOR THE EARLY DIAGNOSIS OF INVASIVE ASPERGILLOSIS (IA) IN LUNG TRANSPLANT RECIPIENTS.
19. Outcomes of Liver Transplantation From Hepatitis C Virus-positive DCD Donors and Its Utilization Among Centers in the United States.
20. Indications, Techniques, and Barriers for Pancreas Transplant Biopsy: A Consensus Perspective From a Survey of US Centers.
21. O Pancreas, Where Art Thou?
22. Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients.
23. Sotrovimab for Treatment of COVID-19 in Solid Organ Transplant Recipients.
24. Association of HHV-6 With Outcomes in CMV-seronegative Liver Transplant Recipients With CMV-seropositive Donors Receiving Preemptive Antiviral Therapy.
25. Simultaneous Pancreas-kidney Transplantation for Type 2 Diabetes Mellitus.
26. How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients.
27. The Times, They are a-Changing: HOPE for HIV-to-HIV Organ Transplantation.
28. Hepatitis C-Positive Kidney Transplant Recipients-When Is The Best Time to Treat With Direct-Acting Antiviral Agents?
29. Performance Characteristics of Galactomannan and β-d-Glucan in High-Risk Liver Transplant Recipients.
30. Cryptococcosis in Patients With Cirrhosis of the Liver and Posttransplant Outcomes.
31. Do no harm: calcium and phosphate supplementation in kidney transplant recipients.
32. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
33. Mycobacterium tuberculosis-associated immune reconstitution syndrome in solid-organ transplant recipients.
34. Cardiac stress test as a risk-stratification tool for posttransplant cardiac outcomes in diabetic kidney transplant recipients.
35. How I treat cryptococcosis in organ transplant recipients.
36. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients.
37. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes.
38. Prevention of cytomegalovirus in organ transplant recipients: cross roads between antiviral and antitumor immunity.
39. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients.
40. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis.
41. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings.
42. Inching closer towards optimization of treatment for latent tuberculosis in liver transplant recipients.
43. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients.
44. Hypercalcemia related to immune reconstitution in organ transplant recipients with granulomatous opportunistic infections.
45. Optimization of outcomes related to cytomegalovirus in organ transplant recipients.
46. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
47. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection.
48. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome.
49. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years.
50. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.